Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
复制标题
通过将骨改性剂从唑来膦酸改为地诺塞麦来改善肾功能
DOI：
--
复制
发表时间：
2016
影响因子：
3.3
通讯作者：
J. Yonese
中科院分区：
文献类型：
--
作者：
Mutsushi Yamasaki;T. Yuasa;S. Uehara;Y. Fujii;Shinya Yamamoto;H. Masuda;I. Fukui;J. Yonese
背景为了帮助选择最佳的骨修饰剂（BMA;唑来膦酸或地舒单抗），我们调查了BMA对骨转移患者肾功能的影响.Materials and MethodsThe本研究包括118例在2012年至2015年期间在我院接受地舒单抗治疗继发于前列腺癌、肾细胞癌和尿路上皮癌的骨转移患者。这些患者的肾功能的临床过程中，唑来膦酸或地舒单抗治疗，进行了回顾性evaluated.ResultsOf的118例谁是在研究期间与地舒单抗治疗，57（48%）以前曾给予唑来膦酸和61（52%）已收到地舒单抗作为一线BMA。从唑来膦酸变更为地舒单抗的原因包括血清肌酐水平升高（26例患者，46%）、患者偏好（16例患者，28%）、静脉输注困难（10例患者，17%）和其他原因（5例患者，9%）。由于血清肌酐水平升高而从唑来膦酸转换为地舒单抗的患者中，肌酐清除率的中位水平在唑来膦酸给药前为59.9 ml/min，在地舒单抗治疗开始时为40.9 ml/min，在地舒单抗给药后3个月为47.5 ml/min，在末次随访时为52.0 ml/min。存在显着差异。结论我们首次证明，一些在唑来膦酸给药后肾功能恶化的患者在改用地舒单抗后成功改善。
BackgroundIn order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases.Materials and methodsThe present study consisted of 118 patients who were treated with denosumab for bone metastases secondary to prostate cancer, renal cell cancer, and urothelial cancer at our hospital between 2012 and 2015. The clinical course of the renal function of these patients, treated with zoledronic acid or denosumab, was retrospectively evaluated.ResultsOf the 118 patients who were treated with denosumab during the study period, 57 (48 %) had previously been administered zoledronic acid and 61 (52 %) had received denosumab as the first-line BMA. The reasons for changing from zoledronic acid to denosumab were increased creatinine serum level (26 patients, 46 %), patient preference (16 patients, 28 %), difficulty with venous infusion (10 patients, 17 %), and other reasons (5 patients, 9 %). The median level of creatinine clearance in the patients who changed from zoledronic acid to denosumab due to increased serum creatinine level was 59.9 ml/min before administration of zoledronic acid, 40.9 ml/min at the beginning of denosumab treatment, 47.5 ml/min at 3 months after administration of denosumab, and 52.0 ml/min at the last follow-up. There were significant differences.ConclusionsFor the first time, we demonstrated that the renal function of some patients, which had deteriorated following zoledronic acid administration, successfully improved after changing to denosumab.
影响因子：
23.4
作者：
Gartrell BA;Coleman RE;Fizazi K;Miller K;Saad F;Sternberg CN;Galsky MD
通讯作者：
Galsky MD
影响因子：
45.3
作者：
Scher, Howard I.;Halabi, Susan;Hussain, Maha
通讯作者：
Hussain, Maha